百乐眠胶囊联合曲唑酮治疗中度抑郁症的临床研究

目的研究百乐眠胶囊联合盐酸曲唑酮片治疗中度抑郁症的临床疗效。方法选取2016年3月—2019年3月在汉中市中心医院进行治疗的120例中度抑郁患者为研究对象,将所有患者随机分为对照组和治疗组,每组各60例。对照组患者口服盐酸曲唑酮片,初始剂量为50 mg/次,次日开始可增加50 mg/次,3次/d;治疗组患者在对照组基础上口服百乐眠胶囊,4粒/次,2次/d。两组患者持续治疗4周。观察两组的临床疗效,比较两组的汉密顿抑郁量表(HAMD)评分、抑郁自评量表(SDS)评分,以及脑源性神经营养因子(BDNF)、多巴胺(DA)、5-羟色胺(5-HT)水平。结果治疗后,对照组和治疗组的总有效率分别为86.67%、96.67%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者HAMD评分和SDS评分均显著降低,同组治疗前后比较差异有统计学意义(P0.05);并且治疗组患者HAMD评分和SDS评分明显低于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组患者BDNF、DA、5-HT水平均显著升高,同组治疗前后比较差异有统计学意义(P0.05);并且治疗组患者BDNF、DA、5-HT水平均明显高于对照组,两组比较差异有统计学意义(P0.05)。结论百乐眠胶囊联合盐酸曲唑酮片治疗中度抑郁症具有较好的疗效,能改善临床症状,调节BDNF、DA、5-HT水平,安全性较好,具有一定的临床推广应用价值。

Clinical study on Bailemian Capsules combined with trazodone in treatment of moderate depression

Objective To study the efficacy of Bailemian Capsules combined with Trazodone Hydrochloride Tablets in treatment of moderate depression. Methods Patients (120 cases) with moderate depression in Hanzhong Central Hospital from March 2016 to March 2019 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Trazodone Hydrochloride Tablets, starting dosage was 50 mg/time, 50 mg/time from the next day, three times daily. Patients in the treatment group were po administered with Bailemian Capsules on the basis of the control group, 4 grains/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and HAMD scores, SDS scores, and the levels of BDNF, DA and 5-HT in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 86.67% and 96.67%, respectively, and there was difference between two groups (P<0.05). After treatment, HAMD scores and SDS scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of BDNF, DA and 5-HT in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Bailemian Capsules combined with Trazodone Hydrochloride Tablets has clinical curative effect in treatment of moderate depression, can improve clinical symptoms, and regulate the levels of BDNF, DA and 5-HT, with good safety, which has a certain clinical application value.